Recent trials investigating glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists (GLP-1RAs) for the treatment of NAFLD have shown promising results. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.